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In 2011, two people meet in a psychiatrist’s waiting room. 
To the untrained eye they have little in common. Patient A 
has a history of brief psychotic episodes characterized by 
persecutory delusions and auditory hallucinations. She is 
married,  with  a  good  job  and  has  been  asympto  matic 
since starting medication three years before. Patient B is 
slow  and  unreactive  in  his  responses,  communi  cates 
poorly,  has  poor  hygiene  and  is  suspicious  of  other 
people. He believes that aliens have implanted a device in 
his head that controls his thoughts, feelings and actions. 
He hears them talking about him and commenting on his 
behavior. He has spent much of the last three years in 
hospital and has few remaining social contacts. Despite 
the  obvious  differences  in  symptomatology  and  illness 
course,  their  treating  psychiatrist  has  diagnosed  them 
both  with  schizophrenia,  prescribes  them  the  same 
medication and enrolls them as participants in a research 
study of schizophrenia.
Schizophrenia  affects  approximately  1%  of  the  adult 
population and reduces life expectancy by an average of 
20 to 25 years through the impact of the disorder on self-
care and physical health, as well as through suicide [1]. At 
the present time the etiological mechanisms under  lying 
schizophrenia  are  poorly  understood.  Schizo  phrenia  is 
diagnosed clinically, based on characteristic symptoms of 
psychosis,  disorganization  and  so  called  ‘negative’ 
symptoms  (representing  a  reduced  range  of  emotional 
expression, reduced production of speech and a lack of 
volition/motivation);  duration  of  illness;  impaired 
functioning; and the exclusion of other disorders such as 
autism  and  bipolar  disorder.  For  clinicians,  identifying 
which  psychotic  patients  have  schizophrenia  requires 
clinical  acumen  and  familiarity  with  the  DSM-IV  or 
ICD-10 diagnostic manuals [2,3]. Psychiatrists generally 
agree on cases where these criteria are met and this has 
helped  standardize  approaches  to  research  and  treat-
ment, but as the vignette highlights, the symptoms are 
heterogeneous and outcome is variable even with treat-
ment. Although the diagnostic criteria are stringent, at 
the level of individual symptoms schizophrenia overlaps 
with other psychiatric disorders, medical disorders and 
even with normal human experience (Figure 1).
Revisions  of  the  criteria  for  clinical  diagnosis  have 
attempted  to  address  such  concerns,  but  the  decision 
making  process  that  underlies  this  process  revolves 
around  criteria  that  are  unlikely  to  reflect  underlying 
biological  mechanisms.  For  example,  in  DSM-IV  the 
requirement for a six-month period of continuous illness 
provides  a  clear  distinction  from  brief  psychotic  dis-
orders, but differs from the one-month criteria specified 
in ICD-10. In DSM-IV at least two characteristic symp-
toms  must  generally  be  present,  namely:  delusions, 
hallucinations,  disorganized  speech,  grossly  abnormal 
psychomotor behavior and negative symptoms. Only one 
symptom  is  required  for  specific  types  of  auditory 
hallucinations (such as afflict patient B) or for delusions if 
they are bizarre. Tellingly, this is likely to change in future 
diagnostic  guidelines  (for  example,  in  DSM-V  due  in 
2013) as such features are not pathognomonic; that is, 
they are also reported in other psychotic conditions. In 
fact,  none  of  the  five  characteristic  symptoms  are 
diagnosis-specific  and  to  satisfy  the  criteria  for 
schizophrenia  other  disorders  (for  example,  psychosis 
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ded. Explicit in the criteria, the negative impact of the 
illness on social and occupational function is part of the 
diagnosis, although this will reflect a myriad of personal, 
family, cultural, societal and medical factors. Attempts to 
differentiate  patients  who  meet  the  diagnostic  criteria, 
such  as  A  and  B,  based  on  clinical  subtypes  such  as 
‘paranoid  type’  or  ‘disorganized  type’  have  not  proved 
fruitful either, as features of the illness can change over 
time. Indeed, these subtypes are likely to be abandoned 
in future guidelines.
Given such a challenging range of clinical phenotypes, 
it  is  not  altogether  surprising  that  animal  models  of 
schizophrenia  based  on  diverse  human  symptoms,  or 
resulting  from  serendipitous  clinical  observation,  have 
yielded few insights and no new therapies [4]. Implicit in 
most models is the assumption that schizophrenia is a 
single  disorder,  but  an  equally  plausible  view,  echoing 
Bleuler’s earlier conceptualization of a ‘group of schizo-
phrenias’ [5], is that the clinical phenotype may capture 
several  or  more  distinct  molecular  pathologies  or 
diseases. However, despite the fact that schizophrenia is 
challenging, it is also a substantially heritable phenotype. 
Figure 1. Indicating the five main symptom domains in schizophrenia. For a diagnosis, symptoms of these generally need to co-occur for one 
month or more. The figure shows how each of these symptom domains overlaps with other disorders.
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genomics may be helpful in guiding researchers towards 
a better understanding of the biological origins of this 
disease or group of diseases.
From	genetic	epidemiology	to	schizophrenia	genes
From  epidemiological  studies  of  risk  in  schizophrenia 
patients  and  their  relatives  it  has  been  suggested  that 
several (or more) susceptibility genes interact with each 
other and with environmental risk to cause illness. This is 
consistent  with  the  common  disease  common  variant 
(CDCV) model, which proposes that multiple common 
alleles each make a small contribution to susceptibility, 
and  may  combine,  together  with  environmental  risk 
factors,  to  cause  disease  when  a  certain  threshold  is 
reached. An alternative view is that susceptibility involves 
the influence of rare genetic variants either contributing 
to a common disease or capturing multiple rare diseases. 
Only  relatively  recently  have  the  required  molecular 
research  tools  become  available  to  begin  empirically 
testing these hypotheses (Figure 2). Both common risk 
variants,  such  as  single  nucleotide  polymorphisms 
(SNPs)  with  a  frequency  of  greater  than  5%  in  the 
population, but with individually small effects (odds ratio 
<1.2) and rare variants with larger effects (odds ratio = 
1.5 to ≥20) have been identified, provoking much specu-
lation about the relative contribution of different classes 
or  mechanisms  of  genetic  risk  and  their  potential 
interaction. And this is speculation, as collectively these 
risk variants at present explain only a modest proportion 
of total schizophrenia heritability (<5%).
Lessons	learned	from	genome-wide	association	
studies
Genome-wide association studies (GWAS) support the 
involvement  of  common  risk  variants  and  implicate  a 
number of specific genetic risk variants. Using a novel 
polygene score method, the International Schizophrenia 
Consortium  identified  substantial  overlap  in  common 
putative risk alleles of small effect across the genome in 
schizophrenia datasets and estimated that these explain 
at  least  one-third  of  total  variation  in  schizophrenia 
liability [6]. The same set of multiple genetic variants of 
small  effect  were  also  associated  in  a  bipolar  disorder 
sample, supporting findings for overlapping risk between 
these disorders from family-based epidemiological studies 
[7]. This polygenic model has received support in a recent 
large meta-analysis of GWAS conducted by the Psychiatric 
GWAS  Consortium  (PGC)  [8]  and  is  informative  in 
suggesting that hundreds of common risk variants may 
be  involved  in  susceptibility  without  confirming  which 
SNPs are contributory.
As  of  autumn  2011,  a  number  of  reported  schizo-
phrenia  GWAS  and  a  meta-analysis  by  the  PGC  have 
provided significant evidence for ten susceptibility loci 
[8-13] (Table 1). In keeping with the epidemiological data 
and polygene score analysis, many of these loci appear to 
confer  liability  to  both  schizophrenia  and  bipolar  dis-
order  [8].  Trying  to  move  from  these  loci,  many  of 
unknown function, to a coherent molecular framework 
for schizophrenia is a daunting task, although one also 
faced in other common diseases, including diabetes and 
inflammatory bowel disease. Individually the variants are 
of modest effect (for example, increasing risk from 1 to 
1.15) and collectively they account for a small proportion 
of  total  variance  in  risk;  findings  that  are  of  limited 
diagnostic  or  prognostic  utility.  For  biologists,  investi-
gating such small and probably subtle effects in model 
systems is challenging and may not be particularly infor-
mative.  However,  the  ultimate  goal  of  GWAS  is  the 
discovery of biological risk pathways underlying complex 
traits  and  there  is  little  reason  to  believe  that  schizo-
phrenia will prove different to other traits where progress 
has  been  made,  including  height  and  blood  pressure 
[14,15].
From the list of identified common schizophrenia risk 
loci, at least two (MIR137 and ZNF804A) appear to have 
a role in regulating other genes. Relatively little is known 
about the role of the microRNA 137 (MIR137) gene in 
brain  function,  although  it  has  been  implicated  in 
neuronal  maturation  and  adult  neurogenesis.  Interest-
ingly, four of the other GWAS-implicated susceptibility 
genes  (TCF4,  CACNA1C,  CSMD1  and  C10orf26)  have 
predicted miR-137 target sites. In the PGC dataset, SNPs 
mapping  to  the  301  high-confidence  predicted  gene 
targets  of  miR-137  were  also  enriched  for  association 
signals,  compared  with  other  genes  of  similar  size  or 
genetic  marker  density,  making  the  MIR13  locus  and 
network an attractive target for further investigation [8].
Larger GWAS datasets are being collected and may be 
useful in identifying additional common risk variants and 
further  informing  biology,  a  brute  force  approach  that 
has been useful with other complex traits as described 
above [14,15]. Having a better estimation of small genetic 
effects  can  be  informative  for  several  reasons.  At  a 
summary level, it will be useful to have better estimates 
of the proportion of schizophrenia heritability captured 
by common SNPs and to know how this overlaps with 
other  disorders.  In  the  International  Schizophrenia 
Consortium  paper,  one  noteworthy  finding  from  the 
polygene  score  analysis  was  that  the  common  risk 
identified extended to bipolar disorder but not to seven 
other  common  medical  disorders,  including  multiple 
sclerosis, diabetes and hypertension [6]. Analyses currently 
underway  are  assessing  whether  schizophrenia  genetic 
risk  extends  across  psychiatric  phenotypes,  including 
autism,  depression  and  attention-deficit  hyperactivity 
disorder (ADHD). This will be important in helping to 
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distinct conditions.
Having better estimates of small effects may also clarify 
whether common risk SNPs cluster in discrete molecular 
pathways; pathway analyses based on current data have 
been  equivocal,  although  providing  some  support  for 
involve  ment of cell adhesion pathways. A related question 
is whether risk pathways capture discrete risk sub  groups 
of  patients  defined  by  symptoms,  clinical  disorder,  or 
some broader liability to developmental disorder? From 
these data it will also be possible to estimate whether a 
liability  threshold  of  common  variants  is  sufficient  to 
cause schizophrenia, and whether this can be applied to 
individual  risk  prediction.  At  present,  the  lesson 
emerging from other disorders is that, where identified 
risk  variants  explain  only  a  small  proportion  of  total 
heritability  (as  is  the  case  now  for  most  diseases),  or 
where heritability is modest, common risk variants are 
unlikely to have the discriminatory power to improve risk 
prediction [16].
Structural	genomic	variation	and	schizophrenia
There is accumulating evidence for involvement of rare, 
genomic structural variation in schizophrenia. The two 
most persuasive schizophrenia genetics findings from the 
pre-genome era emerged from cytogenetic studies. In the 
first, a balanced translocation between chromosomes 1 
and  11,  causing  a  mutation  of  the  gene  disrupted-in-
schizophrenia 1 (DISC1), strongly segregates with mental 
disorder  in  a  large  Scottish  kindred  [17].  Carrying  the 
mutation has a large effect on liability to both schizo-
phrenia and mood disorder. Outside this family, there is 
some evidence that other variants at the DISC1 locus are 
associated  with  other  neuropsychiatric  and  cognitive 
phenotypes, but the translocation has not been identified 
in other families. The second finding is the association of 
schizophrenia  with  22q11.2  deletion  syndrome 
(22q11.2DS; also known as velo-cardio-facial syndrome), 
which has an incidence of 1 in approximately 4,000 live 
births and leads to a varied set of symptoms, including 
physical  defects  and  learning  disabilities.  Phenotypic 
expression of 22q11.2DS is highly variable and can affect 
multiple  organs  and  tissues,  but  carriers  also  have  a 
30-fold increased risk of schizophrenia. Animal models 
have  been  highly  informative  in  clarifying  how  these 
mutations  impact  on  brain  development  and  function 
(reviewed  in  [18,19]).  These  models  represent  rare 
genetic forms, however, and it remains a matter of debate 
whether this limits their construct validity as models of 
schizophrenia [4].
The past five years have seen increased awareness of 
the presence and importance of submicroscopic deletions, 
Figure 2. Models of complex genetic etiology. Risk variants are grouped according to their frequency in the population (x-axis) and their 
penetrance (y-axis). The penetrance of a disease-causing mutation is the proportion of individuals with the mutation who exhibit clinical 
symptoms. Zones A and B indicate risk variation assayed in genome-wide association studies (GWAS), and zone C indicates variants assayed by 
studies of copy number variation (CNV). Zone C also includes rare variants of intermediate penetrance that will be accessible to exomic and 
genomic sequencing (adapted from McCarthy et al. [36]).
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A seminal paper by Walsh and colleagues [20] identified 
an increased rate of novel deletions and duplications of 
genes in schizophrenia cases, particularly those with an 
early age at onset. Following on from the Walsh paper, 
two large consortia studies identified an association of 
copy number change at chromosome 1q21.1 and dele-
tions of chromosome 15q13.3 with schizophrenia [21,22]. 
Subsequent studies have reported evidence for an asso-
ciation  between  schizophrenia  and  more  copy  number 
variations (CNVs), including both chromosomal micro-
deletions  and  microduplications  (reviewed  in  [23,24]). 
Some of these span many genes, but the 2p16.3, 7q36 and 
16p13.2  loci  specifically  implicate  individual  genes 
(NRXN1,  which  encodes  a  synaptic  adhesion  protein, 
VIPR2,  which  encodes  a  neuropeptide  receptor,  and 
C16orf72,  respectively)  [23-25].  Each  of  these  loci  is 
reported to increase schizophrenia risk from two- to ten-
fold, making these interesting targets for further research 
[26-28] (Table 1).
Although individually rare, cumulatively the structural 
mutations identified to date involve approximately 5% of 
cases  of  schizophrenia.  An  unexpected  finding  is  that 
these CNVs also confer risk for a range of other develop-
mental phenotypes, including autism, learning disability, 
ADHD,  seizure  disorder,  other  physical  anomalies  and 
obesity. As an example, carriers of the 15q13.3 deletion 
have an increased rate of schizophrenia (6 to 9%), autism 
(approximately  10%),  learning  disability  (approximately 
50%) and epilepsy (approximately 30%), but a subset have 
no  discernable  clinical  findings  [29].  For  each  of  these 
loci further studies are required to identify whether there 
Table	1.	The	main	replicated	risk	variants	identified	for	schizophrenia	with	their	locations	and	effect	sizes
Confirmed common risk variants for schizophrenia
Chomosome  Variant  P-value  Odds Ratio  95% CI  Gene  Reference
1p21.3  rs1625579  1.5x10-11  1.12  1.09-1.16  MIR 137  8
2p15.1  rs2312147  1.9x10-9  1.09    VRK2  13
2q32.1  rs1344706  2.5x10-11  1.1  1.07-1.14  ZNF804A  9
2q32.3  rs17662626  4.65x10-8  1.2  1.13-1.26    8
6p21.3-p22.1*  rs2021722  2.18x10-12  1.15  1.11-1.19  HLA region  8,10,11,12
8p23.2  rs10503253  1.45x10-8  1.16  1.11-1.21  CSMD1  8
8q21.3  rs7004633  2.75x10-8  1.1  1.07-1.14    8
10q24.32*  rs7914558  2.23x10-8  1.22  1.15-1.29  CNNM2  8
11q24.2  rs12807809  2.8x10-9  1.16  1.09-1.24  NRGN  8,11
18q21.2*  rs12966547  2.35x10-8  1.4  1.28-1.52  TCF4  8,10,11,12
Confirmed rare variant risks for schizophrenia
Chomosome 
CNV type  Position (Mb)  P-value  Odds Ratio  95% CI  Gene  Reference
1q21.1 del  143.8-146.6  2.2x10-8  8.3  3.7-19.9     21,22,23
1q21.1 dup  143.8-146.6  2 x 10-3  3.7  1.5-8.7     23
2p16.3 del  50.7-51.3  5.5x10-9  8.2  3.8-19.4  NRXN1  23,25
3q29 del  197.2-198.83  4x10-4  2.9      23,24
7q36.3 dup  158.7-158.81  8.3x10-5  16.4  3.11, infinity  VIPR2  23,24
15q11.2 del  20.3-20.8  6x10-4  2.73  1.5-4.89    22
15q13.3 del  28.2-30.6  2x10-9  9.9  4.3-24.4    21,22,23
16 dup  9.09-9.12  1x10-4  12.9  2.8-121.4  C16orf72  23
16p11.2 dup  15.0-18.0  1.5x10-12  11.6  5.6-29.3    23
16p13.1 dup  29.5-30.2  7x10-3  3.27  1.29-7.94    26
17p12 del  14.0-15.4  5x10-5  10  not presented    27
22q11 del  17.1-19.9  <1.0x10-16  44  35.9-infinity    23
The Odds Ratio (OR) is a measure of effect size. It is the ratio of the odds of the variant occuring in the group of people with disease versus the ratio in the control 
group.
The 95% confidence interval (CI) gives the range within which the true OR lies with a 95% probability.
CNV denotes a copy number variant, which may either be a deletion (del) or duplication (dup).
An asterisk indicates that more than one variant has been implicated at this locus. Details for rare variants are provided where only one gene is implicated; typically, 
the other CNVs implicate 10 to 20 or more genes.
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22q11.2DS) or whether they involve such a wide range of 
phenotypic effects that syndromal classification will be 
difficult.  Significantly,  this  phenotype  list  does  not 
include bipolar disorder, where evidence for involvement 
of structural variation is more equivocal. However, this 
may reflect sample ascertainment as recent data suggest 
that CNVs contribute to the risk of early onset bipolar 
disorder (Jonathan Sebat, personal communication).
How much of schizophrenia risk involves rare muta-
tions and how many of these require a background of 
other  mutations  or  common  risk  effects  for  disease 
expression? These critical questions will define the rate of 
progress  in  translating  genetic  findings  into  biological 
insights. Although of much larger effect than the common 
variants defined as risk alleles by GWAS studies, most of 
the  CNVs  reported  to  date  occur,  albeit  at  lower 
frequency, in unselected control populations. In parallel 
with  developing  model  systems  for  these  mutations,  it 
will  be  necessary  to  assess  their  penetrance  and  to 
establish whether more subtle phenotypes (for example, 
dyslexia  or  anxiety  disorders)  occur  in  seemingly 
unaffected individuals. Carefully defined control popula-
tions are important: the DISC1 family provide a salutory 
lesson as the original proband had a diagnosis of conduct 
disorder, rather than a major mental illness, and would 
have met control rather than case criteria in the standard 
case-control association study design. This highlights the 
complexity of the task at hand: it may be necessary to re-
evaluate  study  design  -  and  the  results  of  previous 
studies - on the basis of new genetic information.
Studying	sequence-level	mutations	in	
schizophrenia
Exomic and whole genome sequence data will become 
available for hundreds, if not thousands, of schizophrenia 
patients in the next couple of years. What will this teach 
us? The limited reported sequence data currently avail  able 
suggest that there may be an increased rate of potentially 
deleterious de novo mutations in schizo  phrenia patients 
compared to control subjects [30]. For example, an excess 
of  missense  variants  has  been  reported  in  the  gene 
GRIN2B, encoding the NMDA receptor subunit NR2B, in 
schizophrenia  and  autism  but  also  with  other  neuro-
developmental phenotypes [31,32]. Assessing the signifi-
cance of rare or unique mutations across the genome to 
disease manifestation, particularly if these fail to converge 
on the same genes, will be difficult as there may be just 
too many mutations to identify which have a causal role. 
One  obvious  starting  point  will  be  to  assess  sequence 
data at genes implicated by existing GWAS (for example, 
TCF4)  and  structural  variation  studies  (for  example, 
NRXN1).  As  the  number  of  risk  loci  expands  it  will 
become  possible  to  test  specific  hypotheses  based  on 
implicated  risk  pathways,  although  the  success  of  this 
approach will require better pathway annotation. Lessons 
may  also  be  learned  from  severe  neurodevelopmental 
disorders  where  null  mutations  may  have  profound 
phenotypic effects on brain structure but less deleterious 
mutation may result in more subtle phenotypes, which 
could  include  schizophrenia  [33].  As  an  example,  Pitt-
Hopkins syndrome, a developmental disorder with severe 
learning disability, can be caused by haploinsuffiency of 
either of two known schizophrenia risk genes, TCF4 or 
NRXN1.  It  is  still  too  early  to  know  whether  such 
examples are representative, but based on the structural 
variation data it seems reasonable to investigate genetic 
mutations  based  on  data  generated  across  a  range  of 
neurodevelopmental phenotypes.
From	genes	to	biology
This  is  an  interim  phase  in  our  understanding  of  the 
genetic architecture of schizophrenia. Conceptually the 
framework involves hundreds or even thousands of very 
modest risk alleles but also some number of rare muta-
tions  with  a  much  larger  effect  on  risk  for  certain 
individuals. Having rare, high penetrance mutations is a 
significant  breakthrough,  as  it  makes  possible  the 
development of model systems based on biology rather 
than  on  clinical  symptomatology.  This  is  particularly 
appli  cable where individual genes or point mutations are 
involved. Affected individuals become obvious targets for 
studies  ranging  from  clinical  investigation  of  their 
symptomatology,  treatment  response  and  outcome  to 
imaging of their neural circuits and studies of blood cells 
reprogrammed  as  stem  cells  and  differentiated  as 
neurons in culture. In parallel, the mutations themselves 
can be modeled in cellular or animal systems. Increas-
ingly sophisticated methods for examining neural circuits 
in vivo using viral tracing or optogenetics are also becom-
ing  available,  but  are  beyond  the  scope  of  this  article 
(reviewed in [34]).For each implicated mutation it will be 
important to know the resultant cellular and behavioral 
phenotypes,  the  signaling  or  other  mechanisms  that 
result in these phenotypes and whether the phenotypes 
can  be  rescued  by  intervention  with  novel  or  known 
therapeutic  agents.  Taking  the  example  of  DISC1,  we 
know  that  the  normal  regulation  of  neural  progenitor 
proliferation  by  modulation  of  GSK3beta/beta-catenin 
signaling is disrupted in DISC1 mutants and it will be 
interesting  to  see  if  the  same  process  is  disturbed  by 
other  mutations.  Experiments  across  mutations  may 
define whether future therapies target a molecular risk 
mechanism common to most schizophrenia patients, a 
strategy that recent experiments on neuronal cell cultures 
derived  from  four  unrelated  schizophrenia  patients 
suggests  may  be  successful  [35],  or  are  much  more 
focused  on  smaller  groups  based  on  many  molecular 
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are we investigating the clinical phenotype ‘schizophrenia’ 
or  is  this  only  one  phenotypic  outcome  of  different 
neuro  developmental pathologies?
Answering  this  question  will  shape  the  future  of 
nosology and define how psychiatric care is delivered in 
the future. Currently, DSM-IV classification draws a clear 
distinction  between  schizophrenia  and  other  neuro-
develop  mental  disorders.  From  analysis  of  genomic 
structural variation this seems artificial, as a significant 
subset of schizophrenia patients share overlapping mole-
cular  pathology  with  patients  diagnosed  with  other 
developmental phenotypes, including learning disability, 
autism and epilepsy. Will future care to these families be 
delivered  along  existing  guidelines  based  on  clinical 
expertise or defined by molecular etiology?
Risk  mutations  may  arise  de  novo,  but  may  also  be 
inherited,  as  is  the  case  for  75%  of  individuals  with 
15q13.3 microdeletions. Within a family, carrying a risk 
mutation  may  represent  risk  for  a  constellation  of 
develop  mental phenotypes. Systematic and standardized 
assessment  of  mutation  carriers  will  be  required  to 
identify  whether  there  are  core  features  for  specific 
genomic  syndromes,  to  develop  screening  criteria  to 
identify carriers and to define who should be screened. 
Although the known CNVs increase risk for a range of 
adverse  outcomes,  most  CNVs  are  not  ‘causative’  in  a 
deterministic Mendelian genetics sense and their role in 
increasing risk is likely to be dependent on other genetic 
or environmental factors. To provide genetic counseling 
to families, a better model of the molecular framework 
that underlies these phenotypes will be required. Current 
estimates of the penetrance of known risk mutations are 
based on ascertainment from highly selected populations 
(for  example,  patients  with  developmental  disorders) 
who may have a higher burden of other mutations than is 
representative  in  the  general  population.  For  the 
molecular data to be meaningful, prospective studies to 
group  genetic  risk  factors  and  collect  information  on 
environmental  risk  factors  will  be  required.  For 
‘schizophrenia’  this  may  be  challenging  as  the  known 
environ  mental  risk  factors  are  typically  small  (for 
example,  obstetric  complications),  difficult  to  quantify 
(for example, cannabis exposure), or difficult to interpret 
(for example, urban living).
Returning to patients A and B, enrolled as cases in a 
‘schizophrenia’ research study, this may have significant 
ramifications for future schizophrenia studies as we try to 
understand differences in symptoms, treatment response, 
course of illness and outcome evident in clinical popula-
tions.  Recognizing  that  a  proportion  of  patients  carry 
high  penetrance  risk  mutations  may  demarcate  a 
‘syndromal’ form of schizophrenia, or patients at risk of 
neurodevelopmental  phenotypes  including  psychotic 
symptoms, much as is happening within autism spectrum 
disorders  now.  Within  this  ‘syndromal  schizophrenia’ 
group,  further  distinctions  may  be  possible  based  on 
molecular  etiology.  A  corollary  of  identifying  patients 
with more genetic forms of a disorder is that this might 
also identify patients with a less genetic form. It is too 
early to tell whether having different levels of molecular 
risk is associated with differences in symptom severity, 
treatment response or outcome. But this may emerge as 
useful  information  in  advising  patients  on  risk  of 
recurrence,  relapse  prevention  or  therapeutics.  Having 
this information may also influence how doctors interpret 
symptoms: in a carrier of a 15q13.3 deletion, are insidious 
negative  symptoms  due  to  schizophrenia,  reflective  of 
social impairments due to an autistic spectrum disorder, 
or actually just a feature of the neural systems affected? 
In the real world, clinicians know that many patients do 
not fit neatly within existing diagnostic categories. As an 
illustrative  example,  a  patient  may  have  attended 
psychiatric services since childhood and been diagnosed 
with  developmental  delay,  ‘behavioral  problems’ ,  and 
subsequently an autistic spectrum disorder, and in adult-
hood  schizophrenia.  Knowing  that  this  patient  has  a 
patho  genic NRXN1 mutation may provide a much sounder 
basis on which to diagnose or prescribe treatment.
Projecting (speculatively) to the clinic of 2025, it may 
be that for patient A, after the molecular diseases that 
cause schizophrenia are excluded, only a modest burden 
of  common  risk  variants  are  identified.  The  episode  is 
identified  as  proximal  to  a  psychological  stressor;  she 
receives  a  focused  psychotherapy  to  address  how  she 
dealt with the stressor, the risk of recurrence is low and 
pharmacotherapy is not indicated. Patient B is identified 
as having a mutation that has a functional effect on a 
signaling  mechanism,  this  is  known  to  respond  to  an 
existing  therapy,  and  his  medication  is  altered 
appropriately. He also has a significant family history of 
seizure  disorder  and  autism  and  the  family  is  being 
investigated further by clinical geneticists to further our 
understanding of the genetic basis of, and relationships 
amongst, these conditions.
Published: 11 November 2011
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